Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Cl (original) (raw)

Abstract

sparkles

AI

This research analyzes various measures of disease activity in rheumatoid arthritis (RA), including the Patient and Provider Global Assessments, Disease Activity Scores (DAS and DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), and patient-administered scores (PAS and RAPID2). Each assessment tool's methodology, respondent burden, reliability, and validity are discussed, highlighting their strengths and limitations for clinical use.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (123)

  1. Fransen J, Stucki G, van Riel PL. Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum 2003;49 Suppl:S214 -24.
  2. Verhoeven AC, Boers M, van Der Linden S. Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis. Ann Rheum Dis 2000;59:966 -74.
  3. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al, for the Committee on Outcome Measures in Rheumatoid Arthri- tis Clinical Trials. The American College of Rheumatology prelimi- nary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729 -40.
  4. Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol 2006;24 Suppl:S45-51.
  5. Ledingham J, Deighton C, for the British Society for Rheumatology S28 Anderson et al
  6. Standards, Guidelines and Audit Working Group. Update on the Brit- ish Society for Rheumatology guidelines for prescribing TNF␣ block- ers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005;44:157-63.
  7. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gau- joux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964 -75.
  8. Pincus T, Bergman M, Sokka T, Roth J, Swearingen C, Yazici Y. Visual analog scales in formats other than a 10 centimeter horizontal line to assess pain and other clinical data. J Rheumatol 2008;35:1550 -8.
  9. Scott PJ, Huskisson EC. Measurement of functional capacity with visual analogue scales. Rheumatol Rehabil 1977;16:257-9.
  10. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary defi- nition. J Rheumatol 2005;32:2016 -24.
  11. Rohekar G, Pope J. Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. J Rheumatol 2009;36:2178 -82.
  12. Hernandez-Cruz B, Cardiel MH. Intra-observer reliability of com- monly used outcome measures in rheumatoid arthritis. Clin Exp Rheumatol 1998;16:459 -62.
  13. Lassere MN, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol 2001;28:892-903.
  14. Aletaha D, Machold KP, Nell VP, Smolen JS. The perception of rheu- matoid arthritis core set measures by rheumatologists: results of a survey. Rheumatology (Oxford) 2006;45:1133-9.
  15. Nicolau G, Yogui MM, Vallochi TL, Gianini RJ, Laurindo IM, Novaes GS. Sources of discrepancy in patient and physician global assess- ments of rheumatoid arthritis disease activity. J Rheumatol 2004;31: 1293-6.
  16. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discor- dance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005;52:3873-9.
  17. Hanly JG, Mosher D, Sutton E, Weerasinghe S, Theriault D. Self- assessment of disease activity by patients with rheumatoid arthritis. J Rheumatol 1996;23:1531-8.
  18. Strand V, Cohen S, Crawford B, Smolen JS, Scott DL, for the Lefluno- mide Investigators Groups. Patient-reported outcomes better discrim- inate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:640 -7.
  19. Van Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A, et al. Patient-reported health outcomes in a trial of etanercept mono- therapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis 2008;67: 1104 -10.
  20. Scott J, Huskisson EC. Vertical or horizontal visual analogue scales. Ann Rheum Dis 1979;38:560.
  21. Athale N, Sturley A, Skoczen S, Kavanaugh A, Lenert L. A web- compatible instrument for measuring self-reported disease activity in arthritis. J Rheumatol 2004;31:223-8.
  22. Yazici Y, Erkan D, Peterson MG, Kagen LJ. Morning stiffness: how common is it and does it correlate with physician and patient global assessment of disease activity? [letter]. J Rheumatol 2001;28:1468 -9.
  23. Baker PR, Groh JD, Kraag GR, Tugwell P, Wells GA, Boisvert D. Impact of patient with patient interaction on perceived rheumatoid arthritis overall disease status. Scand J Rheumatol 1996;25:207-12.
  24. Ward MM. Clinical measures in rheumatoid arthritis: which are most useful in assessing patients? J Rheumatol 1994;21:17-27.
  25. Berglin E, Lorentzon R, Nordmark L, Nilsson-Sojka B, Rantapaa Dahl- qvist S. Predictors of radiological progression and changes in hand bone density in early rheumatoid arthritis. Rheumatology (Oxford) 2003;42:268 -75.
  26. Rintelen B, Sautner J, Haindl P, Andel I, Maktari A, Leeb B. Compar- ison of three rheumatoid arthritis disease activity scores in clinical routine. Scand J Rheumatol 2009;7:1-7.
  27. Harrington JT. The uses of disease activity scoring and the physician global assessment of disease activity for managing rheumatoid arthri- tis in rheumatology practice. J Rheumatol 2009;36:925-9.
  28. Leeb BF, Sautner J, Leeb BA, Fassl C, Rintelen B. Lack of agreement between patients and physicians perspectives of rheumatoid arthritis disease activity changes. Scand J Rheumatol 2006;35:441-6.
  29. Makinen H, Kautiainen H, Hannonen P, Sokka T. A new disease activity index for rheumatoid arthritis: Mean Overall Index for Rheu- matoid Arthritis (MOI-RA). J Rheumatol 2008;35:1522-7.
  30. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheu- matology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34 -40.
  31. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23 Suppl:S100 -8.
  32. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23 Suppl:S93-9.
  33. Uhlig T, Kvien TK, Pincus T. Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. Ann Rheum Dis 2009;68:972-5.
  34. Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916 -20.
  35. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty- eight-joint counts: development and validation in a prospective lon- gitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44 -8.
  36. Radovits BJ, Fransen J, van Riel PL, Laan RF. Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis. Ann Rheum Dis 2008;67:1127-31.
  37. Van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol 1993;20:538 -41.
  38. Salaffi F, Peroni M, Ferraccioli GF. Discriminating ability of compos- ite indices for measuring disease activity in rheumatoid arthritis: a comparison of the Chronic Arthritis Systemic Index, Disease Activity Score and Thompson's Articular Index. Rheumatology (Oxford) 2000; 39:90 -6.
  39. Fransen J, Hauselmann H, Michel BA, Caravatti M, Stucki G. Respon- siveness of the self-assessed Rheumatoid Arthritis Disease Activity Index to a flare of disease activity. Arthritis Rheum 2001;44:53-60.
  40. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796 -806.
  41. Hensor EM, Emery P, Bingham SJ, Conaghan PG, for the YEAR Con- sortium. Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced? Rheumatol- ogy (Oxford) 2010;49:1521-9.
  42. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and Euro- pean League Against Rheumatism response criteria based on C-reac- tive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedi- mentation rate. Ann Rheum Dis 2009;68:954 -60.
  43. Aletaha D. Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind? Arthritis Res Ther 2006;8: 102.
  44. Shaver TS, Anderson JD, Weidensaul DN, Shahouri SS, Busch RE, Mikuls TR, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008;35:1015-22.
  45. Smolen JS, Aletaha D. What should be our treatment goal in rheuma- toid arthritis today? Clin Exp Rheumatol 2006;24 Suppl:S7-13.
  46. Landewe R, van der Heijde D, van der Linden S, Boers M. Twenty- eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006;65:637-41.
  47. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low: results from RABBIT, the German biologics register. Arthritis Res Ther 2006;8:R66.
  48. Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, et al. Predicting response to anti-TNF treatment in rheumatoid arthri- tis patients. Autoimmun Rev 2009;8:431-7.
  49. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28 C-reactive protein threshold values. Ann Rheum Dis 2007;66: 407-9.
  50. Kuhlow H, Fransen J, Ewert T, Stucki G, Forster A, Langenegger T, et al. Factors explaining limitations in activities and restrictions in par- ticipation in rheumatoid arthritis. Eur J Phys Rehabil Med 2010;46: 169 -77.
  51. Macedo A, Oakley S, Gullick N, Kirkham B. An examination of work instability, functional impairment, and disease activity in employed patients with rheumatoid arthritis. J Rheumatol 2009;36:225-30.
  52. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42:1854 -60.
  53. Prajs K, Flicinski J, Brzosko I, Przepiera-Bedzak H, Ostanek L, Brzosko M. Quality of life and activity of disease in patients with rheumatoid arthritis. Ann Acad Med Stetin 2006;52 Suppl:39 -43. In Polish.
  54. Villaverde V, Balsa A, Cantalejo M, Fernandez-Prada M, Madero MR, Munoz-Fernandez S, et al. Activity indices in rheumatoid arthritis. J Rheumatol 2000;27:2576 -81.
  55. Balsa A, de Miguel E, Castillo C, Peiteado D, Martin-Mola E. Superi- ority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology (Oxford) 2010;49:683-90.
  56. Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Satoh K, Tamai M, et al. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomark- ers in patients with rheumatoid arthritis. Rheumatology (Oxford) 2010;50:962-5.
  57. Fransen J, Uebelhart D, Stucki G, Langenegger T, Seitz M, Michel BA. The ICIDH-2 as a framework for the assessment of functioning and disability in rheumatoid arthritis. Ann Rheum Dis 2002;61:225-31.
  58. Seror R, Tubach F, Baron G, Guillemin F, Ravaud P. Measure of function in rheumatoid arthritis: individualized or classical scales? Ann Rheum Dis 2010;69:97-101.
  59. Van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
  60. Van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999;26:705-11.
  61. Abe A, Ishikawa H, Murasawa A, Nakazono K. Disease activity and the course of elbow joint deterioration over 10 years in the patients with early rheumatoid arthritis. Clin Rheumatol 2008;27:867-72.
  62. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and func- tional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009 -17.
  63. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67:1360 -4.
  64. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010;69:65-9.
  65. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lan- cet 2004;364:263-9.
  66. Prevoo ML, van Riel PL, van 't Hof MA, van Rijswijk MH, van Leeu- wen MA, Kuper HH, et al. Validity and reliability of joint indices: a longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol 1993;32:589 -94.
  67. Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum 1994;37:470 -5.
  68. Lindsay K, Ibrahim G, Sokoll K, Tripathi M, Melsom RD, Helliwell PS. The composite DAS score is impractical to use in daily practice: evidence that physicians use the objective component of the DAS in decision making. J Clin Rheumatol 2009;15:223-5.
  69. Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol 2006;24 Suppl:S29 -32.
  70. Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocili- zumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 2011;63:43-52.
  71. Balsa A, Carmona L, Gonzalez-Alvaro I, Belmonte MA, Tena X, Sanmarti R, et al. Value of Disease Activity Score 28 (DAS28) and DAS28 -3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004;31:40 -6.
  72. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244 -57.
  73. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
  74. Rintelen B, Haindl PM, Maktari A, Nothnagl T, Hartl E, Leeb BF. SDAI/CDAI levels in rheumatoid arthritis patients are highly depen- dent on patient's pain perception and gender. Scand J Rheumatol 2008;37:410 -3.
  75. Soubrier M, Zerkak D, Gossec L, Ayral X, Roux C, Dougados M. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol 2006;33:1243-6.
  76. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 2006;54:2784 -92.
  77. Arya V, Malaviyab AN, Raja RR. CDAI (Clinical Disease Activity Index) in rheumatoid arthritis: cut-off values for classification into different grades of disease activity. Indian J Rheumatol 2007;2:91-4.
  78. Parekh K, Taylor WJ. The Patient Activity Scale-II is a generic indi- cator of active disease in patients with rheumatic disorders. J Rheu- matol 2010;37:1932-4.
  79. Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthri- tis. Arthritis Rheum 2007;57:935-42.
  80. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the Patient Activity Scale (PAS/PAS-II). J Rheumatol 2005;32:2410 -5.
  81. Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991;18:1290 -7.
  82. Anderson J, Sayles H, Curtis JR, Wolfe F, Michaud K. Converting Modified Health Assessment Questionnaire (HAQ), Multidimensional HAQ, and HAQII scores into original HAQ scores using models de- veloped with a large cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2010;62:1481-8.
  83. Wolfe F, Michaud K, Pincus T. Development and validation of the Health Assessment Questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum 2004;50:3296 -305.
  84. Pincus T. A Multidimensional Health Assessment Questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care. Bull NYU Hosp Jt Dis 2007;65:150 -60.
  85. Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, Routine Assess- ment of Patient Index Data 3 (RAPID3), in two abatacept clinical trials: similar results to Disease Activity Score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Ox- ford) 2008;47:345-9.
  86. Pincus T, Sokka T. Can a Multi-Dimensional Health Assessment Ques- tionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores be informative in patients with all rheumatic diseases? Best Pract Res Clin Rheumatol 2007;21:733-53.
  87. Pincus T, Swearingen CJ, Bergman MJ, Colglazier CL, Kaell AT, Ku- nath AM. RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken) 2010;62:181-9.
  88. Pincus T, Yazici Y, Bergman M. A practical guide to scoring a Multi- Dimensional Health Assessment Questionnaire (MDHAQ) and Rou- tine Assessment of Patient Index Data (RAPID) scores in 10-20 sec- onds for use in standard clinical care, without rulers, calculators, websites or computers. Best Pract Res Clin Rheumatol 2007;21:755- 87.
  89. Yazici Y, Bergman M, Pincus T. Time to score quantitative rheuma- toid arthritis measures: 28-joint count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheu- matol 2008;35:603-9.
  90. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity cate- gories compared to disease activity score and clinical disease activity index categories. J Rheumatol 2008;35:2136 -47.
  91. Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, et al. An index of the three core data set patient questionnaire measures dis- tinguishes efficacy of active treatment from that of placebo as effec- tively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003;48:625-30.
  92. Scott DL, Choy EH, Greeves A, Isenberg D, Kassinor D, Rankin E, et al. Standardising joint assessment in rheumatoid arthritis. Clin Rheuma- tol 1996;15:579 -82.
  93. Klinkhoff AV, Bellamy N, Bombardier C, Carette S, Chalmers A, Esdaile JM, et al. An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol 1988;15:492-4.
  94. Thompson PW, Hart LE, Goldsmith CH, Spector TD, Bell MJ, Ramsden MF. Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. J Rheuma- tol 1991;18:661-5.
  95. Barton JL. Systematic review and metaanalysis of patient self-report versus trained assessor joint counts in rheumatoid arthritis. J Rheu- matol 2009;36:2635-41.
  96. Pincus T, Yazici Y, Bergman M, Maclean R, Harrington T. A proposed continuous quality improvement approach to assessment and man- agement of patients with rheumatoid arthritis without formal joint counts, based on quantitative Routine Assessment of Patient Index S30 Anderson et al
  97. Data (RAPID) scores on a Multidimensional Health Assessment Ques- tionnaire (MDHAQ). Best Pract Res Clin Rheumatol 2007;21:789 -804.
  98. Pincus T, Callahan LF, Brooks RH, Fuchs HA, Olsen NJ, Kaye JJ. Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med 1989;110:259 -66.
  99. Callahan LF, Smith WJ, Pincus T. Self-report questionnaires in five rheumatic diseases: comparisons of health status constructs and asso- ciations with formal education level. Arthritis Care Res 1989;2:122- 31.
  100. Castrejon I, Silva-Fernandez L, Bombardier C, Carmona L. Clinical composite measures of disease activity for diagnosis and followup of undifferentiated peripheral inflammatory arthritis: a systematic re- view. J Rheumatol Suppl 2011;87:48 -53.
  101. Rintelen B, Haindl PM, Sautner J, Leeb BA, Deutsch C, Leeb BF. The Rheumatoid Arthritis Disease Activity Index-5 in daily use: proposal for disease activity categories. J Rheumatol 2009;36:918 -24.
  102. Fransen J, Forster A, Uebelhart D, Michel BA. Reliability and respon- siveness of the RADAI, a self-assessed rheumatoid arthritis disease activity index [abstract]. Ann Rheum Dis 2001;60 Suppl:345.
  103. Stucki G, Liang MH, Stucki S, Bruhlmann P, Michel BA. A self- administered Rheumatoid Arthritis Disease Activity Index (RADAI) for epidemiologic research: psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995;38:795-8.
  104. Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and valid- ity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford) 2000;39:321-7.
  105. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Patient- centered rheumatoid arthritis disease activity assessment by a modi- fied RADAI. J Rheumatol 2008;35:1294 -9.
  106. Leeb BF, Sautner J, Mai HT, Haindl PM, Deutsch C, Rintelen B. A comparison of patient questionnaires and composite indexes in rou- tine care of rheumatoid arthritis patients. Joint Bone Spine 2009;76: 658 -64.
  107. Ferraccioli GF, Salaffi F, Troise-Rioda W, Bartoli E. The Chronic Arthritis Systemic Index (CASI). Clin Exp Rheumatol 1994;12:241-7.
  108. Ferraccioli G, Bartoli E, Salaffi F, Peroni M. The Chronic Arthritis Systemic Index: a nomogram to assess the activity and severity of chronic arthritis [letter]. Arthritis Rheum 1993;36:1180 -1.
  109. Choy EH, Khoshaba B, Cooper D, MacGregor A, Scott DL. Develop- ment and validation of a patient-based disease activity score in rheu- matoid arthritis that can be used in clinical trials and routine practice. Arthritis Rheum 2008;59:192-9.
  110. Calvo FA, Calvo A, Berrocal A, Pevez C, Romero F, Vega E, et al. Self-administered joint counts in rheumatoid arthritis: comparison with standard joint counts. J Rheumatol 1999;26:536 -9.
  111. Figueroa F, Braun-Moscovici Y, Khanna D, Voon E, Gallardo L, Luin- stra D, et al. Patient self-administered joint tenderness counts in rheumatoid arthritis are reliable and responsive to changes in disease activity. J Rheumatol 2007;34:54 -6.
  112. Levy G, Cheetham C, Cheatwood A, Burchette R. Validation of pa- tient-reported joint counts in rheumatoid arthritis and the role of training. J Rheumatol 2007;34:1261-5.
  113. Khan NA, Yazici Y, Calvo-Alen J, Dadoniene J, Gossec L, Hansen TM, et al. Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. J Rheumatol 2009;36: 2435-42.
  114. Stucki G, Stucki S, Bruhlmann P, Michel BA. Ceiling effects of the Health Assessment Questionnaire and its modified version in some ambulatory rheumatoid arthritis patients. Ann Rheum Dis 1995;54: 461-5.
  115. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001;28:982-9.
  116. Martin M, Kosinski M, Bjorner JB, Ware JE Jr, Maclean R, Li T. Item response theory methods can improve the measurement of physical function by combining the modified health assessment questionnaire and the SF-36 physical function scale. Qual Life Res 2007;16:647-60.
  117. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activ- ities of daily living and psychological status in the patient-friendly Health Assessment Questionnaire format. Arthritis Rheum 1999;42: 2220 -30.
  118. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208 -13.
  119. Pincus T, Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheu- matol 2003;17:753-81.
  120. Fitzpatrick R, Newman S, Lamb R, Shipley M. A comparison of measures of health status in rheumatoid arthritis. Br J Rheumatol 1989;28:201-6.
  121. Wagner E, Ammer K, Kolarz G, Krajnc I, Palkonyai E, Scherak O, et al. Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years. Rheumatol Int 2007;27:1041-8.
  122. Leigh JP, Fries JF, Parikh N. Severity of disability and duration of disease in rheumatoid arthritis. J Rheumatol 1992;19:1906 -11.
  123. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988;15:1480 -8.

Cited by